Optional callout banner for highlighted news or events
Learn MorePRESS RELEASE: Jabil Acquires Pii to Support Customer's Drug Development, Clinical Trial, and Product Commercialization.
Learn More
We don’t do ordinary. From potent compounds to complex formulations, we take on the projects others run from—and we get it done, no excuses.
Whether it’s aseptic injectables, complex oral dosage forms, or high-potency soft gels, you’ll receive custom, phase-appropriate support throughout your project’s lifecycle to ensure your drug product moves smoothly on its path to market.
We specialize in tackling the tough stuff. As a drug product CDMO with over 30 years of experience in complex formulations, we’re the gritty, determined partner that prioritizes your project when others won’t.
From tiny test batches to full-scale production, we deliver customized solutions on time, every time.
With Pii, you get flexibility, transparency, and straight talk—nothing less.
President and CEO
You can trust that your project is in safe, experienced hands—because we know the stakes are too high for anything less.
How We Ensure Qualityyears of experience in complex formulations
scientists and
support staff
drug product
approvals in 2023
of clients agree we delivered effective solutions
FDA license to operate
unwavering commitment
Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions, today announced the successful acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing, completed February 3, 2025.
HUNT VALLEY, Md.--(BUSINESS WIRE)--Pharmaceutics International, Inc. (Pii), a leading contract development and manufacturing organization (CDMO), has announced a significant expansion of its prefilled syringe (PFS) capabilities with a $3.6 million investment in advanced labeling, fill/finish, and automated visual inspection technologies.
